Published date: October 19, 2021
BioPlus will secure space for promoting new businesses.
BioPlus announced on the 19th that it will acquire 45,837㎡ of land inside Seongbon Industrial Complex in Eumseong-gun, Chungcheongbuk-do for 16.527 billion won.
▲ Bioplus logo.
As of the end of 2020, the transfer amount amounted to 43.57% of the total bioplus assets.
BioPlus will pay 10% of the transfer amount as a down payment and then pay the intermediate payment and balance three times until May 2022.
BioPlus said, “The purpose is to expand its business to biological sanctions such as botulinum toxin, obesity treatment, and virus treatment, and to secure a business site to expand production facilities for hyalucronic acid-based bio-materials.”
BioPlus produces hyaluronic acid fillers. When listed on the KOSDAQ in September this year, it announced that it will push for new businesses such as botulinum toxin, bio-breast and biocarbon, improved obesity treatment and diabetes treatment.
[Business post reporter Lim Hansol]